Armstrong Advisory Group’s AbbVie ABBV Stock Holding History

Armstrong Advisory Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.31M	Sell	9,193 -72	-0.8%	-$15.5K	0.14%	56
2026 Q1	$2.02M	Sell	9,265 -150	-2%	-$33.3K	0.14%	57
2025 Q4	$2.15M	Sell	9,415 -75	-0.8%	-$17.1K	0.15%	54
2025 Q3	$2.2M	Buy	9,490 +10	+0.1%	+$2.04K	0.16%	52
2025 Q2	$1.76M	Sell	9,480 -362	-4%	-$67.3K	0.13%	53
2025 Q1	$1.75M	Hold	9,842	–	–	0.14%	49
2024 Q4	$1.75M	Buy	9,842 +58	+0.6%	+$10.7K	0.14%	49
2024 Q3	$1.93M	Sell	9,784 -49	-0.5%	-$9.14K	0.16%	44
2024 Q2	$1.69M	Sell	9,833 -386	-4%	-$63.9K	0.15%	43
2024 Q1	$1.58M	Hold	10,219	–	–	0.15%	42
2023 Q4	$1.58M	Sell	10,219 -189	-2%	-$27.6K	0.15%	42
2023 Q3	$1.55M	Buy	10,408 +105	+1%	+$15.4K	0.17%	39
2023 Q2	$1.39M	Sell	10,303 -705	-6%	-$103K	0.15%	42
2023 Q1	$1.75M	Sell	11,008 -218	-2%	-$33.3K	0.21%	36
2022 Q4	$1.81M	Buy	+11,226	New	+$1.72M	0.24%	42

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Armstrong Advisory Group's ABBV Position: Q2 2026 in Review

Armstrong Advisory Group reduced its AbbVie (ABBV) stake by 0.78% in Q2 2026, selling an estimated $15.5K and leaving 9,193 shares worth $2.31M. The position accounts for 0.14% of the portfolio, ranked #56.

Armstrong Advisory Group first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Armstrong Advisory Group held 9,193 shares of AbbVie worth $2.31M as of Q2 2026.
Armstrong Advisory Group sold 72 AbbVie shares in Q2 2026, an estimated $15.5K.
AbbVie made up 0.14% of Armstrong Advisory Group's portfolio in Q2 2026, its #56 holding.
Armstrong Advisory Group first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Armstrong Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.